ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources

Robert E. Henkin; John D. Del Rowe; Perry W. Grigsby; Alan C. Hartford; Hossein Jadvar; Roger M. MacKlis; J. Anthony Parker; Jeffrey Y.C. Wong; Seth A. Rosenthal

doi:10.1097/RLU.0b013e318224b814

ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources

Robert E. Henkin, John D. Del Rowe, Perry W. Grigsby, Alan C. Hartford, Hossein Jadvar, Roger M. MacKlis, J. Anthony Parker, Jeffrey Y.C. Wong, Seth A. Rosenthal

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.

Original language	English
Pages (from-to)	e72-e80
Journal	Clinical nuclear medicine
Volume	36
Issue number	8
DOIs	https://doi.org/10.1097/RLU.0b013e318224b814
State	Published - Aug 2011

Keywords

iodine-131
phosphorous-32
radionuclide therapy
radiopharmaceutical
samarium-153
strontium-89
unsealed sources
yttrium-90

Access to Document

10.1097/RLU.0b013e318224b814

Cite this

@article{264516f3ef664210a71ca85a8953dcee,

title = "ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources",

abstract = "This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.",

keywords = "iodine-131, phosphorous-32, radionuclide therapy, radiopharmaceutical, samarium-153, strontium-89, unsealed sources, yttrium-90",

author = "Henkin, {Robert E.} and {Del Rowe}, {John D.} and Grigsby, {Perry W.} and Hartford, {Alan C.} and Hossein Jadvar and MacKlis, {Roger M.} and Parker, {J. Anthony} and Wong, {Jeffrey Y.C.} and Rosenthal, {Seth A.}",

year = "2011",

month = aug,

doi = "10.1097/RLU.0b013e318224b814",

language = "English",

volume = "36",

pages = "e72--e80",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

number = "8",

}

TY - JOUR

T1 - ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources

AU - Henkin, Robert E.

AU - Del Rowe, John D.

AU - Grigsby, Perry W.

AU - Hartford, Alan C.

AU - Jadvar, Hossein

AU - MacKlis, Roger M.

AU - Parker, J. Anthony

AU - Wong, Jeffrey Y.C.

AU - Rosenthal, Seth A.

PY - 2011/8

Y1 - 2011/8

N2 - This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.

AB - This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.

KW - iodine-131

KW - phosphorous-32

KW - radionuclide therapy

KW - radiopharmaceutical

KW - samarium-153

KW - strontium-89

KW - unsealed sources

KW - yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=79960239012&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e318224b814

DO - 10.1097/RLU.0b013e318224b814

M3 - Article

C2 - 21716005

AN - SCOPUS:79960239012

SN - 0363-9762

VL - 36

SP - e72-e80

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 8

ER -

ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this